Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Withdrawn 1Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 10Sarcoma 9Thoracic 4Gynecologic 4Breast 4Tumor-Agnostic 2Lymphoid 2Endocrine 2Dermatologic 2Other hematologic neoplasm 1NET 1Genitourinary 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Hemangiosarcoma 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × ganitumab × Breast × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT00626106 2024-09-19

QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer

NantCell, Inc.

Phase 2 Completed
156 enrolled 16 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01708161 2018-09-13

A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors

Novartis

Phase 1/2 Terminated
47 enrolled 23 charts
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT01479179 2016-10-26

Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡